REFERENCES
[1] Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF,
Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM,
Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee;
LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in
Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi:
10.1056/NEJMoa1603827. Epub 2016 Jun 13. PMID: 27295427; PMCID:
PMC4985288.
[2] Kumarathurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S,
Kristiansen O, Nielsen OW, Haugaard SB, Sajadieh A. Effects of
Liraglutide on Heart Rate and Heart Rate Variability: A Randomized,
Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care. 2017
Jan;40(1):117-124. doi: 10.2337/dc16-1580. Epub 2016 Oct 19. PMID:
27797930.
[3] Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira
GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE,
Anstrom KJ, Shah MR, Braunwald E, Cappola TP; NHLBI Heart Failure
Clinical Research Network. Effects of Liraglutide on Clinical Stability
Among Patients With Advanced Heart Failure and Reduced Ejection
Fraction: A Randomized Clinical Trial. JAMA. 2016 Aug 2;316(5):500-8.
doi: 10.1001/jama.2016.10260. PMID: 27483064; PMCID: PMC5021525.
[4] Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R,
Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW,
Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L.
Effect of liraglutide, a glucagon-like peptide-1 analogue, on left
ventricular function in stable chronic heart failure patients with and
without diabetes (LIVE)-a multicentre, double-blind, randomised,
placebo-controlled trial. Eur J Heart Fail. 2017 Jan;19(1):69-77. doi:
10.1002/ejhf.657. Epub 2016 Oct 28. PMID: 27790809.
[5] Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L,
Zhan S. Impact of GLP-1 receptor agonists on blood pressure, heart rate
and hypertension among patients with type 2 diabetes: A systematic
review and network meta-analysis. Diabetes Res Clin Pract. 2015
Oct;110(1):26-37. doi: 10.1016/j.diabres.2015.07.015. Epub 2015 Aug 13.
PMID: 26358202.
[6] Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J,
Cappola TP, Margulies KB, Drucker DJ. GLP-1 Receptor Expression Within
the Human Heart. Endocrinology. 2018 Apr 1;159(4):1570-1584. doi:
10.1210/en.2018-00004. PMID: 29444223; PMCID: PMC5939638.
[7] Hamedi Z, Mishriky BM, Okunrintemi V, Powell JR, Cummings DM.
GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials.
Diabetes Metab Res Rev. 2021 Jul;37(5):e3436. doi: 10.1002/dmrr.3436.
Epub 2021 Feb 2. PMID: 33440044.
[8] Nreu B, Dicembrini I, Tinti F, Sesti G, Mannucci E, Monami M.
Major cardiovascular events, heart failure, and atrial fibrillation in
patients treated with glucagon-like peptide-1 receptor agonists: An
updated meta-analysis of randomized controlled trials. Nutr Metab
Cardiovasc Dis. 2020 Jun 25;30(7):1106-1114. doi:
10.1016/j.numecd.2020.03.013. Epub 2020 Mar 25. PMID: 32448716.
[9] Nakamura H, Niwano S, Niwano H, Fukaya H, Murakami M, Kishihara
J, Satoh A, Yoshizawa T, Ishizue N, Igarashi T, Fujiishi T, Ako J.
Liraglutide suppresses atrial electrophysiological changes. Heart
Vessels. 2019 Aug;34(8):1389-1393. doi: 10.1007/s00380-018-01327-4. Epub
2019 Feb 14. PMID: 30762094.